Thurston, Springer, Miller, Herd & Titak, Inc. Novo Cure LTD Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $283 Million
- Q2 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Novo Cure LTD stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 509 shares of NVCR stock, worth $7,492. This represents 0.0% of its overall portfolio holdings.
Number of Shares
509Holding current value
$7,492% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NVCR
# of Institutions
272Shares Held
77.1MCall Options Held
751KPut Options Held
293K-
Black Rock Inc. New York, NY12.1MShares$179 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA11.7MShares$172 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.1MShares$164 Million0.0% of portfolio
-
State Street Corp Boston, MA3.01MShares$44.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.38MShares$35 Million0.0% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.54B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...